What is the recommended treatment approach for osteoporosis in adults?

Treatment of Osteoporosis

Bisphosphonates are the first-line pharmacologic treatment for osteoporosis in adults at moderate-to-high fracture risk, based on their proven efficacy in reducing vertebral fractures by 50-70% and hip fractures by ~40%, favorable safety profile, low cost, and availability as generics 1.

Risk Stratification and Treatment Algorithm

Step 1: Assess Fracture Risk

Determine fracture risk based on:

• Bone mineral density (BMD): T-score ≤-2.5 indicates osteoporosis
• Prior fractures: History of vertebral or hip fracture automatically qualifies as high risk
• FRAX score: 10-year probability of major osteoporotic fracture ≥20% or hip fracture ≥3%
• Age and sex: Postmenopausal women and men ≥50 years
• Clinical risk factors: Glucocorticoid use, parental hip fracture, smoking, excess alcohol 1, 2

Step 2: Initiate Treatment Based on Risk Category

Low Risk Patients

• Calcium (1,000-1,200 mg/day) and vitamin D (600-800 IU/day; serum 25-OH vitamin D ≥20 ng/mL)
• Lifestyle modifications: weight-bearing/resistance exercises, smoking cessation, limit alcohol to 1-2 drinks/day
• No pharmacologic treatment needed 3, 1

Moderate-to-High Risk Patients

First-line: Oral Bisphosphonates

• Alendronate or risedronate preferred
• Strong recommendation for high-risk patients; conditional for moderate-risk 1
• Continue calcium and vitamin D supplementation

Second-line alternatives (if bisphosphonates contraindicated or not tolerated):

1. IV bisphosphonates (zoledronic acid) - higher risk profile than oral but effective 3
2. Denosumab (RANK ligand inhibitor) - subcutaneous injection every 6 months 1
   • Critical caveat: Discontinuation causes rebound vertebral fractures; requires transition to bisphosphonate 4

Very High Risk Patients

Consider anabolic agents first, then transition to antiresorptive:

• Very high risk defined as: Recent vertebral fractures, hip fracture with T-score ≤-2.5, multiple fractures, or fracture on osteoporosis treatment 1, 2

Anabolic options:

1. Romosozumab (sclerostin inhibitor) - 12 monthly subcutaneous injections, then transition to bisphosphonate 1
   • Warning: Avoid in patients with high cardiovascular risk (FDA black box warning) 1
2. Teriparatide (PTH analog) - daily subcutaneous injection for up to 2 years 1
   • Higher cost and injection burden than romosozumab
   • Must transition to antiresorptive after completion to maintain gains 1, 4

Step 3: Duration and Monitoring

Bisphosphonate Duration:

• Treat for 5 years (oral) or 3 years (IV zoledronic acid)
• Reassess fracture risk at that point 1
• Drug holiday: Consider 1-2 year break if low-moderate risk after initial treatment to minimize atypical femoral fracture risk 1, 4
• Continue treatment if still high risk (prior hip/vertebral fracture, T-score ≤-2.5, or high FRAX score) 1

Monitoring:

• BMD testing every 1-2 years
• Loss of >5% BMD at spine or >4% at hip over 2 years = treatment failure; consider switching 5
• Bone turnover markers to assess adherence/response

Special Populations

Males with Primary Osteoporosis

• Same algorithm as postmenopausal women
• Bisphosphonates first-line; denosumab second-line 1

Glucocorticoid-Induced Osteoporosis (≥2.5 mg prednisone/day for ≥3 months)

• Age ≥40 years, moderate-to-high risk: Oral bisphosphonate (strong recommendation for high risk) 3, 6
• Age <40 years, moderate-to-high risk: Oral bisphosphonate preferred 3
• Age <40 years, low risk: Calcium and vitamin D only 3

Postmenopausal Women with Low Bone Mass (Osteopenia)

• Generally calcium and vitamin D only
• Consider bisphosphonates only if additional high-risk features present (conditional recommendation) 1

Critical Safety Considerations

Bisphosphonate Rare Adverse Events:

• Osteonecrosis of the jaw: Risk increases with duration >5 years; ensure dental health before starting 1
• Atypical femoral fractures: Risk increases with duration >5 years; consider drug holidays 1, 4

Denosumab:

• Rebound effect: Multiple vertebral fractures can occur 7+ months after discontinuation
• Never stop abruptly; transition to bisphosphonate 4

Romosozumab:

• Cardiovascular events: Increased risk of MI/stroke; contraindicated in recent cardiovascular disease 1
• Limited to 12 months maximum 1

Raloxifene:

• Only for postmenopausal women when other agents inappropriate
• Increases venous thromboembolism and stroke risk 3

Common Pitfalls to Avoid

1. Not treating after fracture: 75% of fracture patients in Spain receive no treatment despite imminent fracture risk 7
2. Stopping denosumab without transition: Always bridge to bisphosphonate 4
3. Indefinite bisphosphonate use: Reassess at 3-5 years; consider drug holidays in appropriate patients 1
4. Using anabolics without antiresorptive follow-up: Gains are lost without transition therapy 1, 4
5. Ignoring calcium/vitamin D: These are foundational for all patients and enhance medication efficacy 1, 5